Pharsight

Nulibry patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7504095 SENTYNL THERAPS INC Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency
Jan, 2025

(7 months from now)

Nulibry is owned by Sentynl Theraps Inc.

Nulibry contains Fosdenopterin Hydrobromide.

Nulibry has a total of 1 drug patent out of which 0 drug patents have expired.

Nulibry was authorised for market use on 26 February, 2021.

Nulibry is available in powder;intravenous dosage forms.

Nulibry can be used as method of treating molybdenum cofactor deficiency type a.

Drug patent challenges can be filed against Nulibry from 26 February, 2025.

The generics of Nulibry are possible to be released after 26 February, 2028.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-342) Feb 26, 2028
New Chemical Entity Exclusivity(NCE) Feb 26, 2026
M(M-286) Oct 27, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using FOSDENOPTERIN HYDROBROMIDE ingredient

NCE-1 date: 26 February, 2025

Market Authorisation Date: 26 February, 2021

Treatment: Method of treating molybdenum cofactor deficiency type a

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

NULIBRY family patents

Family Patents